4h
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially ...
YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially ...
Market Realist on MSN
How Colossal Biosciences uses CRISPR and the safeguards behind the science
Colossal Biosciences is establishing standards for how biotechnology can responsibly support biodiversity conservation in an ...
As organizations increasingly rely on algorithms to rank candidates for jobs, university spots, and financial services, a new ...
A new study published in Genome Research presents an interpretable artificial intelligence framework that improves both the accuracy and transparency of genomic prediction, a key challenge in fields ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results